Literature DB >> 20643516

Pain and mean absorbed dose to the pubic bone after radiotherapy among gynecological cancer survivors.

Ann-Charlotte Waldenström1, Caroline Olsson, Ulrica Wilderäng, Gail Dunberger, Helena Lind, Massoud al-Abany, Åsa Palm, Elisabeth Avall-Lundqvist, Karl-Axel Johansson, Gunnar Steineck.   

Abstract

PURPOSE: To analyze the relationship between mean absorbed dose to the pubic bone after pelvic radiotherapy for gynecological cancer and occurrence of pubic bone pain among long-term survivors. METHODS AND MATERIALS: In an unselected, population-based study, we identified 823 long-term gynecological cancer survivors treated with pelvic radiotherapy during 1991-2003. For comparison, we used a non-radiation-treated control population of 478 matched women from the Swedish Population Register. Pain, intensity of pain, and functional impairment due to pain in the pubic bone were assessed with a study-specific postal questionnaire.
RESULTS: We analyzed data from 650 survivors (participation rate 79%) with median follow-up of 6.3 years (range, 2.3-15.0 years) along with 344 control women (participation rate, 72 %). Ten percent of the survivors were treated with radiotherapy; ninety percent with surgery plus radiotherapy. Brachytherapy was added in 81%. Complete treatment records were recovered for 538/650 survivors, with dose distribution data including dose-volume histograms over the pubic bone. Pubic bone pain was reported by 73 survivors (11%); 59/517 (11%) had been exposed to mean absorbed external beam doses <52.5 Gy to the pubic bone and 5/12 (42%) to mean absorbed external beam doses ≥ 52.5 Gy. Thirty-three survivors reported pain affecting sleep, a 13-fold increased prevalence compared with control women. Forty-nine survivors reported functional impairment measured as pain walking indoors, a 10-fold increased prevalence.
CONCLUSIONS: Mean absorbed external beam dose above 52.5 Gy to the pubic bone increases the occurrence of pain in the pubic bone and may affect daily life of long-term survivors treated with radiotherapy for gynecological cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643516     DOI: 10.1016/j.ijrobp.2010.04.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Sexual function in adolescent and young adult cancer survivors-a population-based study.

Authors:  Maria Olsson; Gunnar Steineck; Karin Enskär; Ulrica Wilderäng; Marianne Jarfelt
Journal:  J Cancer Surviv       Date:  2018-03-05       Impact factor: 4.442

2.  Lower limb lymphedema in gynecological cancer survivors--effect on daily life functioning.

Authors:  Gail Dunberger; Helene Lindquist; Ann-Charlotte Waldenström; Tommy Nyberg; Gunnar Steineck; Elisabeth Åvall-Lundqvist
Journal:  Support Care Cancer       Date:  2013-06-29       Impact factor: 3.603

3.  Chronic pain, health-related quality of life, and employment in working-age cancer survivors.

Authors:  Emily Cox-Martin; Amy Anderson-Mellies; Virginia Borges; Cathy Bradley
Journal:  J Cancer Surviv       Date:  2019-12-11       Impact factor: 4.442

4.  Perception of body odor-an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer.

Authors:  D Alsadius; C Olsson; N Pettersson; S L Tucker; U Wilderäng; G Steineck
Journal:  J Cancer Surviv       Date:  2013-08-23       Impact factor: 4.442

5.  Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study.

Authors:  H Lind; A-C Waldenström; G Dunberger; M al-Abany; E Alevronta; K-A Johansson; C Olsson; T Nyberg; U Wilderäng; G Steineck; E Åvall-Lundqvist
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

6.  Dose optimization strategy of sacrum limitation in cervical cancer intensity modulation radiation therapy planning.

Authors:  Qi Guo; Shang Cai; Jianjun Qian; Ye Tian
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.